The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Neuronal Synuclein Disease Endotypes 2024, 2025Identifying Biomarkers for the Common Mechanism Underlying the Disease Continuum from Parkinson’s Disease to Alzheimer’s Disease
Study Rationale: Disorders such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) share many similarities in their pathology. In particular, both involve accumulation of amyloid-β and alpha...
-
Research Grant, 2024Quantification of Three Previously Identified Biomarkers of Progression in Stage 2/3 of Parkinson’s Disease
Study Rationale: Early indicators for Parkinson’s disease (PD), so-called biomarkers, are needed to identify subjects at risk during the earliest, prodromal stages of disease and to support clinical...
-
LRRK2 Cohort Consortium, 2012Parkinson’s Institute LRRK2 Cohort: Clinical Phenotype, Pre/Non-Motor and Environmental Risk Assessment
Objective/Rationale:
The objective of this award is to better understand the clinical symptoms of patients that carry the most common genetic risk factor for PD the LRRK2 G2019S variant and what role... -
MJFF Research Grant, 2011Ghrelin Concentrations in CSF and Corresponding Serum Samples in PD Patients and Controls
Objective/Rationale:
The aim of this study is to establish a valid method for measuring ghrelin concentrations in human cerebrospinal fluid samples. Ghrelin is an appetite-stimulating hormone with... -
Research Grant, 2017Improving Participation in Clinical Trials in Individuals with Atypical Parkinsonian Syndromes through Virtual Research Visits (ImPaCT-Atypical)
Objective/Rationale:
The Michael J. Fox Foundation's Fox Trial Finder is designed to facilitate and increase the participation of individuals with Parkinson's disease (PD) and degenerative... -
Research Grant, 2016Planning Phase for a Phase IIa Study of Nilotinib in People with Parkinson's Disease
Study Rationale:
Nilotinib, a drug approved for chronic myelogenous leukemia, inhibits the protein c-Abl. Higher brain levels of c-Abl are associated with Parkinson's disease (PD), and laboratory...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.